Abstract
Objective: Hydromorphone is a potent opioid administered as daily extended-release tablets with good tolerance and safety profile. The SS-PAIN study aims to assess the impressions of physicians on the effect of hydromorphone on sleep quality and its safety profile in patients with severe chronic pain in Spain. Material and methods: This is an ecological study of aggregated data collected from physicians who have experience in managing patients with severe chronic pain. Data were collected using a 35-question survey on the last five patients who came to the consultation to treat severe chronic pain. The questions were focused on the effects of extended-release hydromorphone and other opioids on sleep and their safety profile. Results: A total of 89 physicians answered the survey. The average time of their patients’ pain evolution was 10.7 months. Patients treated with hydromorphone had better and more prolonged sleep than with other opioids. According to the physicians, a mean of 19.2% vs 44.8% of patients had poor sleep quality, and 71.1% vs 55.4% slept more than 5 hours/night with hydromorphone or other opioids, respectively. Physicians considered that hydromorphone improved the patients’ quality of life mainly due to the daily dosage (85.4%) and its good safety profile (77.5%). The main aspects considered when administering hydromorphone as a treatment for pain management were polypharmacy (59.6%), adverse events (48.3%), and comorbidities (38.2%), being recommended for the elderly, immunosuppressed patients or those with impaired renal or hepatic function. Physicians considered that constipation (65.2%), somnolence (48.3%) and nausea (44.9%) were the main adverse events of hydromorphone. Nevertheless, hydromorphone was considered to be the opioid with less interactions (83.1%). Conclusions: Physicians consider that, based on the results of their last patients, extended-release hydromorphone is an adequate alternative for treating severe chronic pain due to the beneficial effects on sleep quality and safety profile, leading to the satisfaction of both the patient and the specialist.References
1. Loeser JD, Bonica JJ, Butler SH, Turk DC, Butler SH, Chapman CR, et al. Bonica's Management of Pain: Lippincott Williams & Wilkins; 2001.
2. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287-333.
3. Torralba A, Miquel A, Darba J. Situación actual del dolor crónico en España: iniciativa "Pain Proposal". Rev Soc Esp Dolor. 2014;21(1):16-22.
4. Anekar AA, Cascella M. WHO Analgesic Ladder. Treasure Island (FL): StatPearls; 2021.
5. Holden JE, Jeong Y, Forrest JM. The endogenous opioid system and clinical pain management. AACN Clin Issues. 2005;16(3):291-301.
6. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, et al. Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci U S A. 1997;94(4):1544-9.
7. Paul AK, Smith CM, Rahmatullah M, Nissapatorn V, Wilairatana P, Spetea M, et al. opioid analgesia and opioid-induced adverse effects: A review. Pharmaceuticals (Basel). 2021;14(11):1091
8. Dimsdale JE, Norman D, DeJardin D, Wallace MS. The effect of opioids on sleep architecture. J Clin Sleep Med. 2007;3(1):33-6.
9. Shaw IR, Lavigne G, Mayer P, Choiniere M. Acute intravenous administration of morphine perturbs sleep architecture in healthy pain-free young adults: A preliminary study. Sleep. 2005;28(6):677-82.
10. Quigley C, Wiffen P. A systematic review of hydromorphone in acute and chronic pain. J Pain Symptom Manage. 2003;25(2):169-78.
11. Vallner JJ, Stewart JT, Kotzan JA, Kirsten EB, Honigberg IL. Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. J Clin Pharmacol. 1981;21(4):152-6.
12. Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage. 2005;29(5 Suppl):S57-66.
13. Zheng M, McErlane KM, Ong MC. Hydromorphone metabolites: Isolation and identification from pooled urine samples of a cancer patient. Xenobiotica. 2002;32(5):427-39.
14. Hasselstrom J, Sawe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet. 1993;24(4):344-54.
15. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497-504.
16. Sathyan G, Xu E, Thipphawong J, Gupta SK. Pharmacokinetic investigation of dose proportionality with a 24-hour controlled-release formulation of hydromorphone. BMC Clin Pharmacol. 2007;7:3.
17. Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging. 2010;27(5):417-33.
18. Nalamachu SR, Kutch M, Hale ME. Safety and tolerability of once-daily OROS() hydromorphone extended-release in opioid-tolerant adults with moderate-to-severe chronic cancer and noncancer pain: Pooled analysis of 11 clinical studies. J Pain Symptom Manage. 2012;44(6):852-65.
19. Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliat Med. 2011;25(5):402-9.
20. Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. J Int Med Res. 2008;36(2):343-52.
21. Schuster M, Bayer O, Heid F, Laufenberg-Feldmann R. Opioid rotation in cancer pain treatment. Dtsch Arztebl Int. 2018;115(9):135-42.
22. Palangio M, Northfelt DW, Portenoy RK, Brookoff D, Doyle RT Jr., Dornseif BE, et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage. 2002;23(5):355-68.
23. Shin SH, Lee HS, Kim YS, Choi YJ, Kim SH, Kwon HC, et al. Clinical usefulness of hydromorphone-OROS in improving sleep disturbances in Korean cancer patients: A multicenter, prospective, open-label study. Cancer Res Treat. 2014;46(4):331-8.
24. Li Y, Ma J, Lu G, Dou Z, Knaggs R, Xia J, et al. Hydromorphone for cancer pain. Cochrane Database Syst Rev. 2021;8(8):CD011108.
25. Stannard C, Gaskell H, Derry S, Aldington D, Cole P, Cooper TE, et al. Hydromorphone for neuropathic pain in adults. Cochrane Database Syst Rev. 2016(5):CD011604.
26. World Health Oorganization. Adherence to long-term therapies : Evidence for action. Geneva: World Health Organization; 2003.
27. Hanna M, Thipphawong J, Study G. A randomized, double-blind comparison of OROS hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care. 2008;7:17.
28. Binsfeld H, Szczepanski L, Waechter S, Richarz U, Sabatowski R. A randomized study to demonstrate noninferiority of once-daily OROS() hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Pract. 2010;10(5):404-15.
29. Wang YH, Sun JF, Tao YM, Chi ZQ, Liu JG. The role of kappa-opioid receptor activation in mediating antinociception and addiction. Acta Pharmacol Sin. 2010;31(9):1065-70.
30. Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287-313.
31. Dolati S, Tarighat F, Pashazadeh F, Shahsavarinia K, Gholipouri S, Soleimanpour H. The role of opioids in pain management in elderly patients with chronic kidney disease: A review article. Anesth Pain Med. 2020;10(5):e105754.
32. Nadstawek J, Wartenberg HC, Schenk M, Wirz S. Hydromorphone in elderly patients with polypathia and with severe pain. The Pain Clinic. 2006;18(5-6):403-13.
33. Chang AK, Bijur PE, Davitt M, Gallagher EJ. Randomized clinical trial of an intravenous hydromorphone titration protocol versus usual care for management of acute pain in older emergency department patients. Drugs Aging. 2013;30(9):747-54.
34. Sacerdote P, Bianchi M, Gaspani L, Manfredi B, Maucione A, Terno G, et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg. 2000;90(6):1411-4.
35. Sloan PA, Barkin RL. Oxymorphone and oxymorphone extended release: A pharmacotherapeutic review. J Opioid Manag. 2008;4(3):131-44.
36. Zutler M, Holty JE. Opioids, sleep, and sleep-disordered breathing. Curr Pharm Des. 2011;17(15):1443-9.
37. Huang Y, Xu C, Zeng T, Li Z, Xia Y, Tao G, et al. Intravenous patient-controlled analgesia hydromorphone combined with pregabalin for the treatment of postherpetic neuralgia: A multicenter, randomized controlled study. Korean J Pain. 2021;34(2):210-6.
38. Webster LR, Smith MD, Mackin S, Iverson M. Comparative effects of morning vs. evening dosing of extended-release hydromorphone on sleep physiology in patients with low back pain: A pilot study. Pain Med. 2015;16(3):460-71.
39. Ringe JD, Schafer S, Wimmer AM, Giesecke T. Use of OROS hydromorphone in the treatment of osteoarthritis and osteoporosis: A pooled analysis of three non-interventional studies focusing on different starting doses. Wien Klin Wochenschr. 2012;124(1-2):25-31.
40. Yu S, Shen W, Yu L, Hou Y, Han J, Richards HM. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in Chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study. J Pain. 2014;15(8):835-44.
41. Viscusi ER. Clinical overview and considerations for the management of opioid-induced constipation in patients with chronic noncancer pain. Clin J Pain. 2019;35(2):174-88.